Pyrantel

Quick links to important sections

Pyrantel

Selected form

Method of action: Anthelmintic

Treatment option: Enterobiasis

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Pyrantel

Pyrantel is a foundational anthelmintic medication designed for the localized treatment of common parasitic worm infestations in the gastrointestinal tract, globally recognized for its efficacy and inclusion in essential medicine lists.

Property Description
Active ingredient Pyrantel Pamoate (INN)
Form Oral suspension (liquid), Tablets
Pharmacological class Anthelmintic, Depolarizing Neuromuscular Blocking Agent
General Use Expulsion of parasitic nematodes (roundworms, pinworms)
Origin Synthetic (Pyrimidine derivative)

What Type of Medicine is Pyrantel Pamoate?

Pyrantel is fundamentally defined as an anthelmintic medication, belonging to the pharmacological class of synthetic drugs specifically developed to treat infestations by parasitic worms. The drug utilizes the active compound Pyrantel Pamoate, which is a synthetic pyrimidine derivative. This classification places it among agents designed to act specifically on parasitic organisms residing within the host's body. Pyrantel is a recognized treatment option for specific nematode infections, establishing the medication's standing in public health contexts.

Composition and Available Forms of Pyrantel

The medication is a single-ingredient product where the key active component is the low-solubility salt, Pyrantel Pamoate. Unlike many systemic medications, Pyrantel is primarily administered via the oral route and is commercially available as both a palatable oral suspension and as tablets. The selection of the Pamoate salt is integral to the product's design because it is minimally absorbed by the human gastrointestinal tract. This low systemic absorption is a crucial, differentiating feature that ensures the high concentration of the active anthelmintic agent remains localized within the gastrointestinal lumen, directly contacting the target parasites.

General Purpose and Action Principle

The general therapeutic purpose of Pyrantel is the rapid and safe eradication of specific intestinal nematodes, such as pinworms and roundworms. It achieves this by functioning as a depolarizing neuromuscular agent, which causes the specific and severe spastic paralysis of the susceptible worms. This mechanism is recognized for its quick onset of action. The resulting paralysis causes the worm to lose its physical grip on the intestinal wall, allowing the host's natural peristalsis (bowel movement) to effectively expel the non-viable worms from the body, fulfilling the medication's general use scenario of clearing the digestive tract of infestation.

Regulatory References

  1. NIH/MedlinePlus

What side effects are possible with Pyrantel?

Pyrantel, an anthelmintic medication, is generally associated with mild and transient adverse reactions, primarily affecting the gastrointestinal and nervous systems. Most reported side effects are uncommon.

Adverse Reactions Summary

System-Organ Class Common Adverse Reactions (Frequency Not Defined)
Gastrointestinal Nausea, vomiting, diarrhea, abdominal cramps, anorexia
Nervous System Headache, dizziness, drowsiness, insomnia
Dermatologic/Other Skin rash, elevated liver enzyme levels (transient)

Serious adverse reactions, while rare, may include signs of a severe allergic reaction (e.g., hives, difficulty breathing, swelling of the face or throat). Reported effects in cases of overdose generally involve pronounced gastrointestinal disturbances, central nervous system effects, and superficial skin reactions.

Safety and Restriction Information

Contraindications and Warnings:

  • The drug is contraindicated in individuals with known hypersensitivity to pyrantel or any component of the formulation.
  • Caution is advised in individuals with pre-existing liver disease, severe malnutrition, or anemia.
  • The concurrent use of pyrantel and piperazine is discouraged due to potential opposing pharmacological actions.

Population-Specific Considerations:

  • Children under 2 years of age: Safety and efficacy have not been established; use is generally restricted to the direction of a healthcare provider.
  • Pregnancy (Category C): Use should only occur if the potential benefits justify the potential risks to the fetus. Consultation with a clinician is advised.
  • Driving/Operating Machinery: Due to the potential for dizziness or drowsiness, caution should be exercised when engaging in activities that require mental alertness until the drug's effect is known.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Pyrantel Pamoate overdose is defined by specific, documented clinical manifestations and strict requirements for seeking immediate medical attention. Overexposure to Pyrantel is associated with a risk of severe neuromuscular and central nervous system (CNS) effects.


Documented Clinical Manifestations

Documented overdose presentations include general gastrointestinal disturbance and superficial skin reactions. More serious manifestations officially listed in regulatory information involve the neuromuscular system, such as muscle spasms and severe muscle weakness. Central nervous system effects, including seizures and difficulty breathing (respiratory depression), are also documented outcomes that warrant urgent intervention.


Required Emergency Actions

The severity of the documented manifestations dictates an urgent response. In the event of suspected accidental overdose, regulatory guidance mandates two immediate actions:

  • Contact a Poison Control Center immediately.
  • Seek immediate medical assistance by going to the nearest medical facility for timely treatment.

Management and Support

The required clinical course of action is to provide symptomatic and supportive care to manage the specific overdose manifestations. Regulatory documents do not explicitly state the existence of a specific antidote for Pyrantel overdose; therefore, management relies entirely on officially described supportive measures.

Therapeutic Uses of Pyrantel

Quick Facts: Pyrantel Uses

  • Pinworm Infection (Enterobiasis): An authorized treatment option.
  • Roundworm Infection (Ascariasis): Utilized in clinical management.
  • Hookworm Infection: Employed to address certain infections caused by hookworms.

Pyrantel is a medication intended for the management of specific parasitic worm infections within the gastrointestinal tract. The primary use of this agent is for the treatment of pinworm infection, medically known as enterobiasis, which is a common intestinal infestation.

This medication is also clinically utilized to address infections caused by roundworms (Ascaris lumbricoides), and it may be employed in the therapeutic approach for certain hookworm infections, including those caused by Necator americanus and Ancylostoma duodenale.

The therapeutic purpose of pyrantel is to support the resolution of these intestinal worm infestations. The goal of treatment is to facilitate the clearance of the parasites from the system.

Eligibility and Restrictions for Use

Official Eligibility and Restrictions

Pyrantel's eligibility is strictly defined by regulatory documentation, based on absolute prohibitions and conditional restrictions for specific patient groups.

Absolute Contraindications

Use is absolutely contraindicated in individuals with a known history of hypersensitivity or allergy to pyrantel pamoate or any component of the formulation. Patients with a confirmed intestinal obstruction must also not use the medicine, as explicitly stated in the prescribing information.

Age-Related Eligibility

The medicine is generally approved for use in the general adult population and in children 2 years of age and older. Use is restricted and requires a physician’s direction for children under 2 years old, as safety and efficacy are not fully established by regulatory bodies for this age group.

Conditional Restrictions

Conditional restrictions apply to specific patient health statuses. Individuals with known hepatic impairment (liver disease), severe anemia, or malnutrition require medical guidance before use. Furthermore, the official label advises that pregnant and breastfeeding individuals must consult a physician; use during pregnancy is restricted due to a Category C classification, and its excretion into human milk is unknown.

What should I know about interactions with other medicines?

The official regulatory profile for Pyrantel Pamoate focuses on a limited number of documented interactions, reflecting the drug's minimal systemic absorption. This characteristic reduces the likelihood of complex pharmacokinetic interactions, such as those involving metabolic enzymes or drug transporters.

Official Interaction Statements

Interacting Substance Official Regulatory Classification Interaction Mechanism/Outcome
Piperazine Contraindicated Co-administration/Avoid Pharmacodynamic antagonism, where co-administration may counteract therapeutic effects.
Theophylline Caution (Moderate/Minor) May increase the plasma concentration of Theophylline by an unspecified mechanism.
Food / Beverages No Interaction/No Restriction No mandatory timing separation is required; administration is permitted with or without meals, milk, or fruit juice.

Interaction-Related Restrictions and Cautions

Co-administration with piperazine is discouraged in regulatory documents due to a documented pharmacodynamic antagonism that may lessen the therapeutic effect of both agents. An exposure-altering interaction is established where Pyrantel co-administration may increase plasma levels of theophylline.

A specific regulatory restriction mandates that individuals with liver disease (hepatic impairment) should not take the product unless under the direction of a healthcare professional. This is a required warning acknowledging potential risks in populations with compromised systemic clearance. The overall interaction profile centers entirely on these specific constraints documented by official health authorities.

Mechanism of Action

Molecular Targeting and Spastic Paralysis

Pyrantel Pamoate functions as an agonist at the nicotinic acetylcholine receptors ( nAChRs) located specifically on the susceptible parasitic worms. This molecular interaction forces the receptors to sustain activation, causing a continuous influx of cations that leads to the irreversible depolarization of the worm's muscle membranes. The resulting systemic effect is spastic paralysis, a state where the parasite's muscles lock into a non-stop contraction, which prevents the organism from maintaining muscular coordination and attachment to the host's intestinal wall.


Mechanism of Displacement and Localization Constraint

The resulting spastic paralysis is the mechanistic event that allows for the removal of the parasite. The paralyzed worms are then subject to the host's normal muscular contractions, known as peristalsis, which facilitates physical displacement from the intestinal wall. Crucially, the mechanism is limited by the drug's design: its very low systemic absorption localizes its action strictly to the gastrointestinal lumen, which means the paralytic mechanism applies only to parasites physically located within the gut and does not extend to migrating larval stages or extra-intestinal organisms.

Dosage and Administration Information

How Pyrantel is Used

The administration of Pyrantel (as Pyrantel Pamoate) is structured to ensure appropriate delivery against target parasites in the gastrointestinal tract. This medication is used via the oral route for intestinal infections. Standard use is a single, weight-based dose, making it a short-term course rather than a continuous therapy.


Core Administration Rules

Feature Guideline
Route of Administration Oral route only.
Standard Dosing Schedule A single dose of 11 mg pyrantel base per kilogram of body weight, not to exceed 1 gram total.
Timing in Relation to Meals May be taken flexibly with or without meals, milk, or fruit juice.
Preparation Requirements Oral suspension must be shaken well immediately before measurement and use.
Age Group Authorized for use in children 2 years of age and older, based on the weight calculation.

The dose calculation is based on body weight to ensure delivery of the 11 mg/kg amount of pyrantel base, which is the standardized regimen. For pinworm infection (enterobiasis), the initial single dose is repeated in two weeks to interrupt the parasite's life cycle and manage potential re-infestation, completing the course of treatment. No prior fasting or post-treatment laxatives are required for administration, providing flexibility in patient use. The entire protocol is focused on the short-term, single-dose pattern.

Recent Clinical Evidence

Research evidence / Overview of studies for Pyrantel

Pyrantel Pamoate was evaluated in research exploring specific parasitic worm infections, including pinworm, roundworm, and hookworm. The evidence base consists mainly of clinical trials where the medicine was evaluated in comparison to placebo or other agents. The findings describe patterns observed in the studies related to parasite clearance from the gastrointestinal system.


Evidence for Use in Pinworm Infection (Enterobiasis)

Research examining pinworm infection includes Randomized Controlled Trials (RCTs) and systematic reviews that established the initial clinical foundation for this medicine. These studies primarily focused on measuring the Cure Rate (CR), which is the study outcome that measures the proportion of individuals who are egg-negative after the study intervention, as well as tracking the rate of infection recurrence. Research was observed in both children and the adult members of their households to understand transmission and control within family units.

Clinical trials consistently reported measurements of the Cure Rate in the short-term evaluation periods. However, studies also described patterns of re-infection in populations where treatment was observed in household contacts when treatment was not applied simultaneously. The long-term effects are not fully established regarding sustained infection control.


Evidence for Use in Roundworm Infection (Ascariasis)

The evidence base for roundworm infection relies on a large collection of Systematic Reviews and Meta-analyses. These research scenarios pool data from numerous RCTs, where pyrantel was included as a comparison arm alongside other agents. The primary outcomes measured in these studies were the Cure Rate (CR) and the Egg Reduction Rate (ERR), study outcomes that monitor the parasite egg count after intervention.

Findings from these large analyses reported measurements of the Cure Rate in the single-dose regimen across the aggregated patient data. The collected data largely concentrates on a short-term follow-up period, typically up to six weeks, providing limited information for long-term outcomes.


What is Still Uncertain in Pyrantel Research

For hookworm infection, the certainty remains low due to inconsistent measured outcomes in trials where pyrantel was included as a comparison arm. Evidence quality varies across studies, particularly older trials, and comparative evidence is lacking for some alternative treatment approaches. Furthermore, data for certain groups remain insufficient; research provides context but not individual predictions.

Key Studies & References Efficacy of single-dose anthelminthic treatments for soil-transmitted helminthiasis: a systematic review and network meta-analysis

Frequently Asked Questions (FAQ)

Common questions about Pyrantel (FAQ)

Q: Does Pyrantel work for all types of worms or just certain ones?

A: Official drug documents define the use of pyrantel for specific parasitic worms. These typically include pinworm (Enterobius vermicularis), roundworm (Ascaris lumbricoides), and certain types of hookworm. The medicine is designed to target only these particular species of intestinal parasites.


Q: How long after taking Pyrantel can I expect to see results?

A: Studies and official information indicate that pyrantel is designed to have a quick onset of action. It works by causing a type of continuous muscle contraction, known as spastic paralysis, in the susceptible worms. This effect leads to the rapid loss of the worm’s ability to attach to the intestinal wall, allowing for their expulsion.


Q: Is Pyrantel a prescription medicine or can it be bought over the counter?

A: Pyrantel Pamoate is classified as an Over-the-Counter (OTC) medicine in its approved formulation for the treatment of pinworm. This means it can often be purchased without a prescription. Any use for conditions other than pinworm, or use outside of the approved OTC directions, would be under the direction of a healthcare professional.


Q: Do I need to change my diet when taking Pyrantel?

A: According to the official product information, the medicine can be taken at any time of day, with or without meals, milk, or fruit juice. The regulatory documents do not specify any mandatory dietary modifications as a requirement for taking the medicine.


Q: Is Pyrantel the same drug as Pyrantel Pamoate?

A: The official active ingredient in the medication is Pyrantel Pamoate, which is a salt form designed for minimal absorption in the gut. 'Pyrantel' is often used as the common, abbreviated name for the drug. The drug is administered as the Pamoate salt in the vast majority of products.


Q: What is the difference between an over-the-counter and prescription use of Pyrantel?

A: When sold Over-the-Counter (OTC), Pyrantel is licensed and indicated specifically for pinworm infection only. If a healthcare provider recommends it for another type of parasitic infection or in a certain clinical setting, that would constitute a use under prescription or medical supervision.


Q: Does alcohol interact with Pyrantel?

A: Although no specific drug-to-alcohol interaction is listed in official labeling, general patient safety information notes that side effects like dizziness or drowsiness are reported, which may be increased by concurrent alcohol use.


Q: What should I do if I accidentally take too much Pyrantel?

A: Official warnings state that in case of accidental overdose, immediate professional medical help or contact with a Poison Control Center is appropriate. This guidance ensures prompt and appropriate management of any severe effects.


Q: Can Pyrantel interact with vitamins or herbal supplements?

A: Official labeling contains a general caution regarding concurrent use with other substances. The label suggests that information regarding all supplements, vitamins, and other treatments be shared with a healthcare provider before the product is used.


Q: How long does Pyrantel stay in my system?

A: Due to its design for minimal systemic absorption, very little pyrantel enters the bloodstream, and it primarily works locally in the gut. For most healthy individuals, the drug is eliminated rapidly after administration.


Q: What happens if Pyrantel does not seem to work for me?

A: If signs of the infection or symptoms persist after the recommended administration of the medication, official guidance is to consult a healthcare provider. They can determine the necessary next steps or check for other types of worm presence.


Q: Is there a taste associated with the liquid form of Pyrantel?

A: The official product labeling for the oral suspension form often describes the product as being flavored to make it easier to take, especially for children. The medication is described as 'palatable' in nature, with some formulations noted as 'vanilla custard flavored.'


Q: Why is Pyrantel sometimes given to an entire family?

A: For infections like pinworm, official instructions may advise treating all household members at the same time, unless a doctor advises otherwise. This approach is taken because these infections are easily transmitted within close contacts, and treating the household helps manage the potential for rapid re-infestation.


Q: Are there long-term side effects associated with Pyrantel use?

A: Pyrantel is administered as a single, short-term treatment, and is not intended for chronic use. The known adverse effects are generally mild and temporary, occurring during or shortly after this limited treatment period. Data concerning long-term effects is not typically included in the official labeling for this limited course of treatment.


Q: Can Pyrantel interact with medications for high blood pressure?

A: Official drug documents list only specific drug-to-drug interactions. General safety advice is that information on all ongoing medications, including those for high blood pressure, be reviewed with a healthcare provider before use.


Q: How quickly does Pyrantel leave the body?

A: Because the medicine is designed for minimal absorption and localized action in the gut, the majority of the drug is rapidly cleared from the system. Official data indicates that most of the drug is eliminated through waste soon after administration.


Q: Is Pyrantel used for prevention or only for treatment?

A: The official indication and usage statement for Pyrantel is for the treatment of pinworms and other specific worm infections. It is not licensed or intended for use as a general preventative agent.


Q: Can Pyrantel interact with stomach acid reducers?

A: The drug label lists only specific interactions (Piperazine and Theophylline). General safety advice is that information on all ongoing medications, including over-the-counter products like acid reducers, be reviewed with a healthcare provider before use.


Q: Is it necessary to have a confirmed diagnosis before taking Pyrantel?

A: For self-treatment (OTC use), the label includes instructions for recognizing a pinworm infection. However, official guidance indicates that if there is any uncertainty about the diagnosis, a healthcare provider should be consulted to ensure the condition is correctly identified.


Q: Does taking Pyrantel cause a noticeable change in the color of waste?

A: Noticeable changes to the color of stool are not listed among the commonly reported side effects or adverse reactions in official product labeling for Pyrantel. Reported gastrointestinal effects typically include cramping or diarrhea.


Q: Does taking Pyrantel affect birth control pills?

A: Birth control pills are not listed as a known interacting substance in the official drug documentation. Nonetheless, the general safety advice is that information on all ongoing medications be reviewed with a healthcare provider before use.


Q: What is the chemical class that Pyrantel belongs to?

A: Pyrantel is a member of the tetrahydropyrimidines chemical class. It is a synthetic derivative of the pyrimidine compound, which places it among agents specifically designed to treat parasitic infections.


Q: Are there different uses for Pyrantel in different countries?

A: The core purpose of Pyrantel is universally defined as an anthelmintic for intestinal nematodes. While the primary indication remains consistent globally, the specific salt used and exact licensed indications may vary slightly depending on the regional regulatory body.


Q: What does the term 'palatable' mean for the liquid form of Pyrantel?

A: The term 'palatable' is used in official labeling to describe a liquid preparation that is pleasant-tasting and easy to swallow. The suspension is often formulated with a flavoring agent, such as vanilla custard, to ensure better acceptance by patients.

How should Pyrantel be stored and disposed of?

Pyrantel Pamoate must be stored and handled according to specific conditions defined by regulatory labeling to maintain product integrity and ensure household safety.

Storage Requirements

Condition Requirement (Official Labeling)
Temperature Store at controlled room temperature, between 15 C and 30 C (59 F and 86 F).
Protection Tablets must be protected from moisture and heat.
Freezing The oral suspension must NOT FREEZE.

All forms of the medication must be stored out of reach of children as a mandatory safety requirement. The oral suspension should be stored in an upright position. The product should not be used if the tamper-evident seal is broken.

Disposal

Official instructions direct that all unused or expired Pyrantel Pamoate must be disposed of according to local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Pyrantel found in:

A-Z Index: